Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.027 | 0.7 |
mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.7 |
mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | ZSTK474 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.7 |
mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |